KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Debt to Equity (2016 - 2025)

Ionis Pharmaceuticals has reported Debt to Equity over the past 17 years, most recently at $0.94 for Q4 2025.

  • Quarterly results put Debt to Equity at $0.94 for Q4 2025, up 965.86% from a year ago — trailing twelve months through Dec 2025 was $0.94 (up 965.86% YoY), and the annual figure for FY2025 was $0.94, up 965.86%.
  • Debt to Equity for Q4 2025 was $0.94 at Ionis Pharmaceuticals, down from $1.02 in the prior quarter.
  • Over the last five years, Debt to Equity for IONS hit a ceiling of $1.02 in Q3 2025 and a floor of $0.02 in Q1 2023.
  • Median Debt to Equity over the past 5 years was $0.11 (2022), compared with a mean of $0.25.
  • Biggest five-year swings in Debt to Equity: tumbled 76.45% in 2022 and later skyrocketed 1421.0% in 2025.
  • Ionis Pharmaceuticals' Debt to Equity stood at $0.08 in 2021, then plummeted by 65.97% to $0.03 in 2022, then surged by 699.23% to $0.22 in 2023, then tumbled by 60.4% to $0.09 in 2024, then soared by 965.86% to $0.94 in 2025.
  • The last three reported values for Debt to Equity were $0.94 (Q4 2025), $1.02 (Q3 2025), and $1.0 (Q2 2025) per Business Quant data.